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Background
Colorectal cancer is the second-leading cause
of cancer-related deaths in the United States and
the third most frequently diagnosed cancer in the
U.S. and Canada.1-3 Both men and women are at
risk for colon cancer. It is more common in those
who are 50 years of age or older; risk increases
with age. Those with a family history of
colorectal cancer or colorectal polyps are also at
increased risk for developing colorectal cancer. 1-3
The U.S. Preventative Services Task Force
(USPSTF) recommends that initial screening be
performed for all men and women who are 50
years of age or older and who are at average risk
for colorectal cancer.
They classify this
recommendation as grade “A” based on clinical
evidence from well-designed, well-conducted
studies demonstrating that screening improves
health outcomes where benefits substantially
outweigh harms. Those who are higher risk
should have initial screening at an earlier age.4
The USPSTF screening options for colorectal
cancer include: home fecal occult blood testing
(FOBT), flexible sigmoidoscopy, the combination
of home FOBT and flexible sigmoidoscopy,
colonoscopy, and double-contrast barium enema.
Traditional FOBT products using a fecal guaiac
smear test include Hemoccult, Seracult, and
Coloscreen.
The Task Force states that the choice of
screening method should be based on the patient
preferences, medical contraindications, patient
adherence, and available testing resources and
follow-up. They further state that “there are
insufficient data to determine which screening
strategy is best in terms of the balance of benefits
and potential harms or cost-effectiveness. It is
unclear whether the increased accuracy of
colonoscopy compared with alternative screening
methods offsets the procedure’s additional
complications, inconvenience, and costs.”4

Testing intervals vary with the specific
screening method.
Annual FOBT, ten year
intervals for colonoscopy, five year intervals for
flexible sigmoidoscopy or double-contrast barium
enemas are usual recommendations for averagerisk patients. Average risk patients include: those
without inflammatory bowel disease or autosomal
inherited colorectal cancers, and those without a
family history for colorectal neoplasia.3,4 With
increased risk for colorectal cancer, screening
intervals shorten. Whenever a positive screening
test occurs, a follow-up colonoscopy is
recommended.3,4
Colorectal screening recommendations of the
National Comprehensive Cancer Network, the
American Cancer Society, the American College
of Surgeons, the American College of
Obstetricians and Gynecologists, and the
American Academy of Family Physicians are all
similar to those of the USPSTF.3,4
Screening guidelines from the Canadian
Association of Gastroenterology and the Canadian
Digestive Health Foundation recommend biennial
FOBT using guaiac-based or immunochemical
testing.
They also recommend flexible
sigmoidoscopy every five years, flexible
sigmoidoscopy combined with FOBT every five
years, double contrast barium enema every five
years, or colonoscopy every ten years for those
individuals at average risk.2
Newer screening technologies for colorectal
cancer include CT colonography (virtual
colonoscopy), immunochemical fecal occult blood
tests (iFOBT or FIT), stool screening using
molecular markers, and capsule video endoscopy.5
The American Cancer Society’s (ACS) Colorectal
Cancer Advisory Group has recommended only
iFOBT as an accepted screening method. In 2002,
the ACS added iFOBT to their recommendation
list as an annual alternative to FOBT.6
The USPSTF does not recommend digital
rectal exam or use of a single office FOBT using a
More. . .
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stool sample obtained by digital rectal exam.7
Collins, et al in a recent prospective cohort study
concluded that single digital FOBT is a poor
screening method and cannot be recommended as
a single test.
Only 4.6% of patients with
advanced proximal neoplasia had positive results
with a single digital FOBT test. They conclude
that if a patient is screened using this single
office-based method and results are negative, the
patient should be further screened with at-home
six-sample FOBT testing or another screening
method [Evidence level B; clinical cohort study].8

Screening Test Accuracy, Detection Ability,
and Reliability
The USPSTF Clinical Guidelines provide an
evidence-based summary of colorectal cancer
screening characteristics.7,9
FOBT – The sensitivity of FOBT varies with
the testing procedure depending on use of a
hydrated or dehydrated specimen. Sensitivity of a
single test is estimated at approximately 40% but
increases to between 50% and 60% if the
specimen is rehydrated. Rehydration refers to the
addition of distilled water to the sample just
before slide development. Single test specificity
is estimated at 96% to 98%. Rehydration of the
specimen reduces specificity to approximately
90%.7 Sensitivity refers to the ability of the test to
produce a positive result in a patient with
colorectal cancer.
Specificity relates the
probability that the test will produce a negative
result in a patient who does not have colorectal
cancer.
Guaiac-based FOBTs have been thought to
produce false-positive results when patients have
ingested red meat, fresh fruits, or vegetables.
Heme contained in red meat and peroxidases
contained in fruits and vegetables can cause these
false results.9,10 Fresh stool specimens do not
allow degradation of vegetable peroxidases which
can sometimes cause false-positive results.9 A
meta-analysis of five randomized trials found that
positivity rates do not seem to be affected by
dietary restrictions where unrehydrated, guaiacbased FOBTs were used [Evidence level A; highquality meta-analysis (quantitative systematic
review)].25
Chronic aspirin or non steroidal antiinflammatory agents (NSAIDs) have been thought
to produce false-positives.11 In a study by Kahi et
al, the authors concluded that aspirin and NSAID

use is not a risk factor for false-positive FOBTs
[Evidence level B; clinical cohort study].12
Ingestion of ascorbic acid can cause falsenegatives due to inhibition of the guaiac
reaction.10
Sigmoidoscopy
–
Single
screening
sigmoidoscopy detects 68% to 78% of advanced
neoplasia.9 Approximately seven cancers and 60
large or high-risk polyps are detected per 1,000
examinations.7 Sigmoidoscopy visualizes only
the lower half of the colon.7
FOBT and Sigmoidoscopy – One-time
screening detects 76% of advanced neoplasia.
The combination of these two methods may
increase detection yields.9
Double-contrast Barium Enema – One-time
screening sensitivity for cancer or large polyps is
approximately 48% with a range of 24% to 67%.9
Colonoscopy – The sensitivity for large
adenomas is 90% and is probably higher for
cancer.9 The estimated sensitivity for small
polyps (< one centimeter) is 75%.7,9

Immunochemical Fecal Occult Blood Tests
(iFOBT)
In 2002, the American Cancer Society added
iFOBT to their recommendation list as an annual
alternative to FOBT.6
In 2003, the Centers for Medicare and
Medicaid Services CMS) issued a decision memo
for screening immunoassay FOBT supporting
iFOBT. Their decision states that “the test
appears to have modestly better test performance
characteristics and patient compliance compared
to existing methods for detecting fecal occult
blood.”13
IFOBT products include Hemoccult ICT
available in the U.S. and Canada, as well as
Hemosure One-Step, immoCARE, Instant-View
FOBT, InSure, and MonoHaem in the U.S.5
Immunochemical fecal occult blood tests use
antibodies to detect the globin portion of human
hemoglobin. If hemoglobin is present, the test
antibody attaches to its antigens producing a
positive test result. Because the test is specific for
human hemoglobin, there are fewer false-positive
tests. Meats, fruits, vegetables, and as well as
aspirin, NSAIDs, and ascorbic acid do not cause
problems. The tests are intended to detect lower
gastrointestinal bleeding.
In a study by Morikawa, et al, iFOBT
sensitivity for advanced neoplasia was 27.1% and
More. . .
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65.8% for cancer. Test specificity was 95.1% for
advanced neoplasia and 94.6% for cancer. The
test product used in the study was Magstream
1000/Hem SP which was a predecessor to
HemeSelect, now Hemoccult ICT.14
Greenberg, et al compared the sensitivities and
specificities for Hemoccult II (FOBT) with
HemeSelect (older predecessor of Hemoccult ICT)
and FlexSure (later predecessor of Hemoccult
ICT) [iFOBTs].15 The following table identifies
these comparisons:

Sensitivity,
cancer
Specificity,
cancer
Sensitivity,
adenoma >
1 cm
Specificity,
adenoma >
1 cm

Hemoccult
II
85.7%

HemeSelect

FlexSure

83.3%

87.5%

92.8%

88.2%

86.2%

20.5%

37.1%

35.9%

91.5%

88.3%

85.6%

In general, iFOBT has a higher sensitivity for
cancer but probably lower specificity compared
with guaiac-based FOBT.
Hemoccult ICT is supplied as a three card
patient test kit. Each card has two specimen
collection zones. Patients are instructed to place
two different swabs of the collected stool on each
collection zone. Three kits are provided so that
the patient will collect a stool sample on three
consecutive days. The test analytical sensitivity is
approximately 300 mcg hemoglobin per gram of
feces (mcg/Hb/g) compared with Hemoccult and
Hemoccult II at approximately 750 mcg/Hb/g.26
The suggested list price for a patient kit is $2.50.
Each kit comes with a mailing envelope so that
the specimens can be mailed or brought back to
the health care professional’s office.16
Hemosure One-Step kit contains a collection
pad for capturing the stool specimen, a collection
tube with a poke spiral applicator for insertion
into six sites of the stool specimen, and a mailing
envelope.
Analytical test sensitivity is
approximately 50 mcg/Hb/g of stool. Only one
stool specimen is used. The suggested list price
for the kit $10.00.17
The immoCARE product provides a stool
specimen collection stick and bottle of buffer
solution. The patient places the stool-containing

swab into the bottle of buffer solution. Once
received by a health care professional, the
specimen-bottle is shaken, the tip of the bottle is
broken and two drops are applied to a test
cassette. The results can be read in five minutes.
A single stool sample is used. The approximate
analytical test sensitivity is 30 mcg/Hb/g of feces.
The suggested list price for immoCARE is
$15.40.18
Instant-View FOBT II is available with a
specimen collection tube, used as a sample
applicator, and a cassette. Using the applicator,
the sample is placed on the cassette. It provides a
visual result in five to ten minutes upon addition
of a stool swab sample. Analytical test sensitivity
is approximately 50 mcg/Hb/g of feces. Only one
stool specimen is used. The suggested list price is
$9.50 per test.19
The InSure patient kit consists of a test card
with a specimen sampling brush and a mailing
envelope. With InSure, the stool sample is
collected by brushing the surface of the stool in
the toilet bowl. The sample is then applied with
the brush to the test card. The process is repeated
with a second sample. The patient mails the
completed test to Quest Diagnostics laboratory for
processing. The analytical test sensitivity is about
50 mcg/Hb/g of feces.20
MonoHaem uses a three card two specimen
application per card process. The patient kit
contains cards, applicators, and a storage bag for
return to the healthcare professional office.
Approximate test sensitivity is 1,000 mcg/Hb/g to
2,000 mcg/Hb/g of feces. The suggested list price
is $2.10 per kit.21
All of the above iFOBT FDA approved
products are Clinical Laboratory Improvement
Amendments (CLIA) waived tests.
Current Procedural Terminology (CPT-4)
codes have been approved by CMS for Medicare
billing of iFOBT. They are G0328QW for testing
as a cancer screen and 82274QW for any use
other than as a cancer screen for CLIA waived
iFOBT. The reimbursement is $22.22.22,23

Commentary
These new immunochemical fecal occult blood
tests generally provide a higher sensitivity for
FOBT screening when compared with guaiac tests
and equal convenience for patients using at-home
testing. Increased stool sampling frequency from
a single collection to two or three consecutive day
More. . .
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sampling increases test sensitivity24 and may help
identify intermittent bleeding. Repeated sampling
may however, decrease test compliance.
Clinically, they eliminate some of the past
concerns regarding false-positive or false-negative
test results with guaiac-based FOBTs.
Immunochemical FOBTs are generally not
available for patient purchase at pharmacies; they
are supplied to physician offices, laboratories, or
clinics. ImmoCARE is available under the name,
ColonCARE, at some pharmacies for patient
purchase. ColonCARE is identical to immoCARE.
Despite the method chosen for colorectal
cancer screening, the most important aspect is
patient completion of routine periodic testing by
all average-risk men and women who are 50 years
of age or older. Those who are at a higher risk
should undergo routine periodic screening at an
earlier age.
Users of this document are cautioned to use their own
professional judgment and consult any other necessary
or appropriate sources prior to making clinical
judgments based on the content of this document. Our
editors have researched the information with input
from experts, government agencies, and national
organizations. Information and Internet links in this
article were current as of the date of publication.

Levels of Evidence
In accordance with the trend towards Evidence-Based
Medicine, we are citing the LEVEL OF EVIDENCE
for the statements we publish.
Level
A

B

C
D

Definition
High-quality randomized controlled trial (RCT)
High-quality meta-analysis (quantitative
systematic review)
Nonrandomized clinical trial
Nonquantitative systematic review
Lower quality RCT
Clinical cohort study
Case-control study
Historical control
Epidemiologic study
Consensus
Expert opinion
Anecdotal evidence
In vitro or animal study
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Adapted from Siwek J, et al. How to write an evidence-based
clinical review article. Am Fam Physician 2002;65:251-8.

References
1.

Anon. Colorectal cancer, let’s break the silence,
screen for life, National Colorectal Cancer Action
Campaign,
Center for Disease Control and

14.

Prevention,
CDC publication #099-6010, May
1999.
http://ww.cdc.gov/cancer/screenforlife.
(Accessed September 6, 2005).
Leddin D, Hunt R, Champion M, et al. Canadian
Association of Gastroenterology and the Canadian
Digestive Health Foundation: guidelines on colon
cancer screening.
Can J Gastroenterol
2004;18:93-9.
Anon. Practice Guidelines in Oncology – v.1.2005,
Colorectal screening. National Comprehensive
Cancer
Network,
Inc.
http://www.nccn.org/professionals/physician_gls/P
DF/colorectal_screening.pdf.
(Accessed
September 7, 2005).
Anon.
Screening for colorectal cancer:
recommendation and rationale. Ann Intern Med
2002;137:129-31.
Levin B, Brooks, D, Smith RA, Stone A. Emerging
technologies in screening for colorectal cancer: CT
colonography, immunochemical fecal occult blood
tests, and stool screening using molecular markers.
CA Cancer J Clin 2003;53:44-55.
Smith RA, Cokkinides V, Eyre HJ. American
Cancer Society guidelines for early detection of
cancer, 2005. CA Cancer J Clin 2005;55:31-44.
U.S. Preventive Services Task Force. Screening
for Colorectal Cancer: Recommendations and
Rationale. July 2002. Agency for Healthcare
Research
and
Quality,
Rockville,
MD.
http://www.ahrq.gov/clinic/3rduspstf/colorectal/color
r.htm. (Accessed September 8, 2005).
Collins JF, Lieberman DA, Drubin TE, et al.
Accuracy of screening for fecal occult blood on a
single stool sample obtained by digital rectal
examination: a comparison with recommended
sampling practice. Ann Intern Med 2005;142:81-5.
Pignone M, Rich M, Teutsch SM, et al. Screening
for colorectal cancer in adults at average risk: a
summary of the evidence for the U.S. Preventative
Services Task Force. Ann Intern Med 2002;7:13241.
Allison JE. Colon cancer screening guidelines
2005: the fecal occult blood test option has become
a better FIT. Gastroenterology 2005;129:745-48.
O’Mara NB.
Aspirin and nonsteroidal antiinflammatory agents and their effect on fecal occult
blood tests. Pharmacist’s Letter/Prescriber’s Letter
2005;21(3):210310.
Kahi CJ, Imperiale TF. Do aspirin and nonsteroidal
anti-inflammatory drugs cause false-positive fecal
occult blood test results? A prospective study in a
cohort of veterans. Am J Med 2004;117:837-41.
Anon. Centers for Medicare & Medicaid Services,
Medicare Coverage Database, Decision memo for
screening immunoassay fecal-occult blood test
(CAG-00180N).
November
4,
2003.
http://www.cms.hhs.gov/mcd/viewdecisionmemo.as
p?id=87. (Accessed September 10, 2005).
Morikawa T, Kato J, Yamaji Y. et al. A comparison
of the immunochemical fecal occult blood test and
total colonoscopy in the asymptomatic population.
Gastroenterology
2005;129:422-28.

More. . .
Copyright © 2005 by Therapeutic Research Center
Pharmacist’s Letter / Prescriber’s Letter ~ P.O. Box 8190, Stockton, CA 95208 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
www.pharmacistsletter.com ~ www.prescribersletter.com

(Detail-Document #211007: Page 5 of 5)
15. Greenberg PD, Bertario L, Gnauck R, et al. A
prospective multicenter evaluation of new fecal
occult blood tests in patients undergoing
colonoscopy. Am J Gastroenterol 2000;95:1331-8.
16. Personal communication. Beckman Coulter, Inc.
Fullerton, CA 92834. September 2005.
17. Product information.
Hemosure One-Step
Immunological
FOBT.
http://hemosure.com/product2.asp?categoryID=He
mo100. (Accessed September 12, 2005).
18. Product
information.
immoCARE.
http://www.careproductsonline.com/professional/
immocare/index.php.
(Accessed September 9,
2005).
19. Personal communication. Alfa Scientific Designs,
Inc. Poway, CA 92064. September 2005.
20. Personal communication. Enterix, Inc. Edison, NJ
08837. September 2005.
21. Personal communication. Chemicon International,
Inc. Temecula, CA 95290 September 2005.
22. Department of Health & Human Services (DHHS)
CMS Manual System, Tests granted waived status
under
CLIA.

23.

24.

25.

26.

http://www.cms.hhs.gov/clia/waivetbl.pdf.
(Accessed September 11, 2005).
Anon.
CPT codes.
Beckman Coulter, Inc.
http://www.hemoccultfobt.com/healthcare/health_C
PT_Codes.htm. (Accessed September 8, 2005).
Yamamoto M, Nakama H.
Cost-effectiveness
analysis of immunochemical occult blood screening
for colorectal cancer among three fecal sampling
methods. Hepatogastroenterology 2000;47:396-9.
Pigone M, Campbell MK, Carr C, Phillips C. Metaanalysis of dietary restrictions during fecal occult
blood testing. Eff Clin Pract 2001. Available at:
http://wwwacponline.org/journals/ecp/julaug01/pign
one.htm. (Accessed September 15, 2005).
Technology Evaluation Center, Blue Cross and
Blue Shield Association. Assessment program:
immunochemical versus guaiac fecal occult blood
tests. July 2004;19:1-27.

Cite this Detail-Document as follows: New take-home screening tests for colon cancer.
Letter/Prescriber’s Letter 2005;21(10):211007.

Pharmacist’s

®

®

The most practical knowledge in the least time…
3120 West March Lane, P.O. Box 8190, Stockton, CA 95208 ~ TEL (209) 472-2240 ~ FAX (209) 472-2249
Copyright © 2005 by Therapeutic Research Center

Subscribers to Pharmacist’s Letter and Prescriber’s Letter can get Detail-Documents, like this one, on any
topic covered in any issue by going to www.pharmacistsletter.com or www.prescribersletter.com

